These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 22273029

  • 1. One-year post-primary antibody persistence and booster immune response to a DTaP-IPV//PRP~T vaccine (Pentaxim) given at 18 - 19 months of age in South African children primed at 6, 10 and 14 weeks of age with the same vaccine.
    Madhi SA, Cutland C, Jones S, Groome M, Ortiz E.
    S Afr Med J; 2011 Nov 28; 101(12):879-83. PubMed ID: 22273029
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
    Thisyakorn U, Pancharoen C, Chuenkitmongkol S, Ortiz E.
    Southeast Asian J Trop Med Public Health; 2009 Mar 28; 40(2):282-94. PubMed ID: 19323013
    [Abstract] [Full Text] [Related]

  • 3. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
    Tregnaghi M, Zambrano B, Santos-Lima E.
    Pediatr Infect Dis J; 2012 Jan 28; 31(1):e24-30. PubMed ID: 22157567
    [Abstract] [Full Text] [Related]

  • 4. Antibody persistence after primary and booster doses of a pentavalent vaccine against diphtheria, tetanus, acellular pertussis, inactivated poliovirus, haemophilus influenzae type B vaccine among Thai children at 18-19 months of age.
    Chotpitayasunondh T, Thisyakorn U, Pancharoen C, Chuenkitmongkol S, Ortiz E.
    Southeast Asian J Trop Med Public Health; 2012 Mar 28; 43(2):442-54. PubMed ID: 23082595
    [Abstract] [Full Text] [Related]

  • 5. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
    Lin TY, Wang YH, Huang YC, Chiu CH, Lin PY, Chen CJ, Chavand P, Ortiz E.
    Int J Infect Dis; 2007 Nov 28; 11(6):488-95. PubMed ID: 17349809
    [Abstract] [Full Text] [Related]

  • 6. Antibody persistence at 18-20 months of age and safety and immunogenicity of a booster dose of a combined DTaP-IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) following primary vaccination of healthy infants in the People's Republic of China.
    Li RC, Li FX, Li YP, Hou QM, Li CG, Li YN, Chen FS, Hu XZ, Su WB, Zhang SM, Fang HH, Ye Q, Zeng TD, Liu TX, Li XB, Huang YN, Deng ML, Zhang YP, Ortiz E.
    Vaccine; 2011 Nov 21; 29(50):9337-44. PubMed ID: 22001281
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity and safety of a DTaP-IPV//PRP~T vaccine (Pentaxim) booster dose during the second year of life in Indian children primed with the same vaccine.
    Dutta AK, Verghese VP, Pemde H, Mathew LG, Ortiz E.
    Indian Pediatr; 2012 Oct 21; 49(10):793-8. PubMed ID: 22791675
    [Abstract] [Full Text] [Related]

  • 8. Long-term immunogenicity assessment of a DTaP-IPV//PRP-T vaccine given at 2, 4, 6 and 18-19 months of age, and immunogenicity and safety of a DTaP-IPV vaccine given as a booster dose at 4 to 6 years of age in Thai children.
    Pancharoen C, Chotpitayasunondh T, Chuenkitmongkol S, Ortiz E.
    Southeast Asian J Trop Med Public Health; 2012 May 21; 43(3):687-98. PubMed ID: 23077849
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity and safety of a pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type B conjugate combination vaccine (Pentaxim) with hepatitis B vaccine.
    Dutta AK, Verghese VP, Pemde HK, Mathew LG, Ortiz E.
    Indian Pediatr; 2009 Nov 21; 46(11):975-82. PubMed ID: 19955579
    [Abstract] [Full Text] [Related]

  • 10. A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children.
    Aquino AG, Brito MG, Doniz CE, Herrera JF, Macias M, Zambrano B, Plennevaux E, Santos-Lima E.
    Vaccine; 2012 Oct 05; 30(45):6492-500. PubMed ID: 22863658
    [Abstract] [Full Text] [Related]

  • 11. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants.
    Madhi SA, Koen A, Cutland C, Groome M, Santos-Lima E.
    Pediatr Infect Dis J; 2013 Aug 05; 32(8):889-97. PubMed ID: 23538523
    [Abstract] [Full Text] [Related]

  • 12. A Randomized Controlled Study of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine for Primary and Booster Vaccinations of Healthy Infants and Toddlers in Latin America.
    López P, Arguedas Mohs A, Abdelnour Vásquez A, Consuelo-Miranda M, Feroldi E, Noriega F, Jordanov E, B Chir S, Zambrano B.
    Pediatr Infect Dis J; 2017 Nov 05; 36(11):e272-e282. PubMed ID: 28719500
    [Abstract] [Full Text] [Related]

  • 13. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
    Lagos R, Kotloff K, Hoffenbach A, San Martin O, Abrego P, Ureta AM, Pines E, Blondeau C, Bailleux F, Levine MM.
    Pediatr Infect Dis J; 1998 Apr 05; 17(4):294-304. PubMed ID: 9576383
    [Abstract] [Full Text] [Related]

  • 14. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses.
    Heininger U, DTP-HBV-IPV-059 Study Group, DTP-HBV-IPV-096 Study Group, Sänger R, Jacquet JM, Schuerman L.
    Vaccine; 2007 Jan 22; 25(6):1055-63. PubMed ID: 17049692
    [Abstract] [Full Text] [Related]

  • 15. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
    Tejedor JC, Moro M, Ruiz-Contreras J, Castro J, Gómez-Campderá JA, Navarro ML, Merino JM, Martín-Ancel A, Roca J, García-del-Río M, Jurado A, Díez-Delgado FJ, Omeñaca F, García-Sicilia J, Boceta R, García-Corbeira P, Jacquet JM, Collard A, Schuerman L, Spanish DTaP-HBV-IPV-097 Study Group.
    Pediatr Infect Dis J; 2006 Aug 22; 25(8):713-20. PubMed ID: 16874171
    [Abstract] [Full Text] [Related]

  • 16. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
    Halperin SA, Tapiéro B, Dionne M, Meekison W, Diaz-Mitoma F, Zickler P, Rubin E, Embree J, Bhuyan P, Lee A, Li M, Tomovici A.
    Pediatr Infect Dis J; 2014 Jan 22; 33(1):73-80. PubMed ID: 24346596
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.
    Klein NP, Abu-Elyazeed R, Cheuvart B, Janssens W, Mesaros N.
    Hum Vaccin Immunother; 2019 Jan 22; 15(4):809-821. PubMed ID: 30444673
    [Abstract] [Full Text] [Related]

  • 18. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
    Vesikari T, Forstén A, Desole MG, Ferrera G, Caubet M, Mesaros N, Boutriau D.
    Pediatr Infect Dis J; 2013 May 22; 32(5):521-9. PubMed ID: 23190785
    [Abstract] [Full Text] [Related]

  • 19. Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children.
    Halperin SA, Langley JM, Hesley TM, Zappacosta PS, Radley D, Smith B, Hoffenbach A, Boslego J, Silber JL.
    Hum Vaccin; 2005 May 22; 1(6):245-50. PubMed ID: 17012871
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated Haemophilus Influenzae type b polysaccharide for primary vaccination at 2, 3, 4 or 3, 4, 5 months of age in infants in China.
    Li RC, Li FX, Li YP, Hou QM, Li CG, Li YN, Chen FS, Hu XZ, Su WB, Zhang SM, Fang HH, Ye Q, Zeng TD, Liu TX, Li XB, Huang YN, Deng ML, Zhang YP, Ortiz E.
    Vaccine; 2011 Feb 24; 29(10):1913-20. PubMed ID: 21219984
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.